Novo Nordisk has reduced its sales and profit growth predictions for 2025. The company cites lower expectations for Wegovy in the U.S. obesity market. They also mention slower growth for Ozempic in the U.S. diabetes market. Wegovy's penetration in international markets is also below expectations. The revised sales growth is now projected at 8%-14%.